The Pharma Data

JUNE 2, 2022

A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. billion to be paid upon the achievement of certain paediatric clinical development milestones. The bacterium Streptococcus pneumoniae causes pneumococcal disease. About Pneumococcal disease.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

MAY 31, 2022

A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. billion to be paid upon the achievement of certain paediatric clinical development milestones. The bacterium Streptococcus pneumoniae causes pneumococcal disease. CAGR: Compound Annual Growth Rate; **CER: Constant Exchange Rate.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

DECEMBER 24, 2020

Most antibody drugs and vaccines have been developed to target parts of the spike protein. These include remdesivir, baricitinib, dexamethasone and three antibody drugs. Antibody drugs were also developed as targeted COVID-19 treatments. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111